Krish Ramadurai
Partner @ Harmonix Fund
Krish Ramadurai is a Partner at Harmonix Fund—an early-stage venture capital fund investing at the intersection of healthcare, life sciences, and deep technology. He is a multi-published scientific author and former researcher at Harvard University’s Belfer Center for Science and International Affairs, the Taubman Center for State and LocalGovernment, and the Massachusetts Institute of Technology. Furthermore, he is an alumnus of Harvard University, Washington University in St. Louis, and the University of Illinois at Urbana-Champaign.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Krish Ramadurai invests in
Stages Krish Ramadurai invests in
Countries Krish Ramadurai invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 6 (60%)
- Artificial Intelligence 5 (50%)
- Health Care 3 (30%)
- Therapeutics 3 (30%)
- Medical 2 (20%)
Stage
- Seed 4 (40%)
- Series A 4 (40%)
- Pre-Seed 1 (10%)
- Funding Round 1 (10%)
Country
- United States 7 (70%)
- United Kingdom 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
chromie Health
|
Chromie Health is an AI-driven healthcare company focused on improving scheduling and workflow efficiency. It uses technology to help healthcare teams manage appointments and operations more smoothly. The company’s goal is to reduce scheduling challenges and save staff time. Overall, it aims to make healthcare coordination faster, smarter, and moreefficient. | $2M / Pre-Seed / May 14, 2026 | |
WearLinq
|
WearLinq is a provider of wearable health monitoring and diagnosis solutions. The company's device records a multi-lead ECG and transmits it in real-time with AI to detect typical irregular heart rhythms, including a normal heart rhythm, aFib, bradycardia, and tachycardia, allowing users to discover history and trends, set reminders, andconnect directly with physicians. | $14M / Series A / Dec 17, 2025 | |
ALIGNMT AI
|
ALIGNMT AI is a software company that offers a comprehensive AI governance and risk management platform for healthcare organizations. | $6.5M / Seed / Aug 28, 2025 | |
Therna Biosciences
|
Therna Biosciences is a medicines development company that specializes in designing RNA therapeutics programme. | $10M / Seed / Aug 26, 2025 | |
Tahoe Therapeutics
|
Tahoe Therapeutics develops AI-powered tools to simulate human cell responses and guide drug discovery. It operates a platform called Mosaic that produces large-scale single-cell datasets detailing how drug molecules interact with diverse patient cells, with initial applications in oncology. It open-sources its Tahoe-100M dataset, comprisinghundreds of millions of single-cell profiles, to train AI models that build virtual cell models for therapeutic insights. A recent funding round enabled the creation of an even larger dataset, targeting one billion cell datapoints and one million drug-patient interactions, designed to fuel next-generation precision medicines | $30M / Aug 11, 2025 | |
|
Tahoe Therapeutics
|
Tahoe Therapeutics develops AI-powered tools to simulate human cell responses and guide drug discovery. It operates a platform called Mosaic that produces large-scale single-cell datasets detailing how drug molecules interact with diverse patient cells, with initial applications in oncology. It open-sources its Tahoe-100M dataset, comprisinghundreds of millions of single-cell profiles, to train AI models that build virtual cell models for therapeutic insights. A recent funding round enabled the creation of an even larger dataset, targeting one billion cell datapoints and one million drug-patient interactions, designed to fuel next-generation precision medicines | $30M / Series A / Aug 11, 2025 | |
Parallel Bio
|
Parallel Bio develops tools that help in the discovery and development of immunotherapies, to eliminate current barriers and create the fastest path to a drug that works. Parallel Bio's platform combines best-in-class human immune organoids with computational methods to generate unprecedented insights into human health and disease. | $21M / Series A / Jun 11, 2025 | |
Stately Bio
|
Stately Bio is the trade-off between measuring cells and keeping them alive. Our patented ML technology measures cell identity, behavior, and maturation—all directly from live-cell, label-free imaging. | $12M / Seed / May 01, 2025 | |
Ataraxis
|
AI-based diagnostic platform that helps develop personalized treatment plans | $20.4M / Series A / Mar 05, 2025 | |
Ignota Labs
|
Ignota Labs recognizes that safety errors during the drug discovery process can result in expensive setbacks and delays in bringing life-changing medications to market. Ignota Labs world leading AI methods, which include deep learning and machine learning approaches, are intended to examine complicated molecular data and provide accurate toxicitypredictions. | $6.9M / Seed / Feb 26, 2025 |
Co-Investors
About Harmonix Fund
Harmonix invests in Health & Bio-IT and deep tech companies advancing human health. We focus on Seed to Series B and partner with experienced teams with strong communication, execution, and traction. We are a multi-disciplinary team consisting of scientists, researchers, operators, entrepreneurs, and industry experts with over 70 years ofcumulative experience.
Harmonix Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Krish Ramadurai
Partner
|
|||
Anthony DeFeo
Managing Director of Marketing and Investor Relations
|
|||
Cofield Mundi
Partner
|
|||
Katya Kohen
Partnership and Network Lead
|
|||
Maximilian Winter
Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Krish Ramadurai invest in?
Krish Ramadurai invests primarily in Biotechnology, Artificial Intelligence and Health Care startups, most often at Seed and Series A stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Krish Ramadurai?
Public channels for Krish Ramadurai include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Krish Ramadurai last invest?
The most recent investment recorded for Krish Ramadurai closed in May 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
